

Syngene

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area,
IV Phase, Jigani Link Road,
Bengaluru 560 099, Karnataka, India

T +91 80 6891 8000

CIN: L85110KA1993PLC01493

www.syngeneintl.com

Ref: Syn/CS/SE/Reg 30/2021-22/Apr/02

April 01, 2021

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 30 of SEBI Listing Regulations, we wish to inform you that the Company has been informed on March 31, 2021, of the conversion of Compulsorily Convertible Debentures of Immuneel Therapeutics Private Limited into equity shares resulting in acquisition of 7.78 % shareholding in the latter.

Other details as required to be disclosed under aforesaid Regulation 30 read with clause 1 of Para A of Annexure I of SEBI Circular dated September 9, 2015, are enclosed as 'Annexure A'. Kindly take the same on record.

The above-mentioned information will also be available on the website of the Company www.syngeneintl.com.

We request you to kindly take this information on record and oblige.

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary & Compliance Officer

Sr. no.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc	Immuneel Therapeutics Private Limited. Turnover as on March 31, 2020 is Nil.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	Yes, the transaction would be considered as a related party transaction. Ms Kiran Mazumdar Shaw, the Non-Executive chairperson and Promoter of the Company is a director of Immuneel Therapeutics Private Limited and holds 7.28% of the equity capital of the said company. The transaction is on an arms length basis.
3	Industry to which the entity being acquired belongs;	Biotechnology
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Conversion of Compulsorily Convertible Debentures as per the terms already disclosed in the Annual Report of the Company for FY 2019-20.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not required
6	Indicative time period for completion of the acquisition	Conversion process is completed
7	Nature of consideration - whether cash consideration or share swap and details of the same	Conversion of Compulsorily Convertible Debentures into 2020 equity shares
8	Cost of acquisition or the price at which the shares are acquired	4,950 unsecured compulsorily convertible debentures of face value Rs. 10/- each converted to 1 equity share of Rs. 49,500/- (Face value of Rs. 10/- and premium of Rs. 49,490). Aggregate value of the converted shares is Rs. 9,99,90,000.
9	Percentage of shareholding / control acquired and /or number of shares acquired	2020 equity shares corresponding to 7.78% of the share capital
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 year turnover, country in which the acquired entity has presence and any other significant information (in brief)	Immuneel Therapeutics Private Limited was incorporated on 20 th Dec 2018. Turnover in the previous years has been Nil. The Company is engaged in the activity of developing Oncology Therapies.